{"id":1887,"date":"2002-12-01T12:08:00","date_gmt":"2002-12-01T11:08:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie"},"modified":"2002-12-01T12:08:00","modified_gmt":"2002-12-01T11:08:00","slug":"ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie","title":{"rendered":"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie"},"content":{"rendered":"<p>Da\u00df Angiotensin-II-Rezeptor-Antagonisten (ARA) etwa gleich positive Effekte wie ACE-Hemmer (ACEI) bei der Indikation Herzinsuffizienz haben, wird gemeinhin angenommen. Durch aufwendiges Marketing haben es die Hersteller der ARA in den letzten Jahren jedoch verstanden, den ARA sogar eine gewisse \u00dcberlegenheit anzudichten. Diese Legende hat durch die OPTIMAAL-Studie (OPtimal Therapy In Myocardial infarction with the Angiotensin II [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Da\u00df Angiotensin-II-Rezeptor-Antagonisten (ARA) etwa gleich positive Effekte wie ACE-Hemmer (ACEI) bei der Indikation Herzinsuffizienz haben, wird gemeinhin angenommen. Durch aufwendiges Marketing haben es die Hersteller der ARA in den letzten Jahren jedoch verstanden, den ARA sogar eine gewisse \u00dcberlegenheit anzudichten. Diese Legende hat durch die OPTIMAAL-Studie (OPtimal Therapy In Myocardial infarction with the Angiotensin II [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[130,316,309,312,314,313,315,317,320,311,307,319,310,308,180,321,2508,306],"class_list":["post-1887","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-captopril","tag-herzinsuffizienz","tag-losartan","tag-optimaal-studie","tag-sartane"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1887"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1887\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}